Determinants of adherence in a cohort of Belgian HIV patients: a pilot study

References

• Sasse A, Verbrugge R, van Beckhoven D. Epidemiologie van aids en HIV-infectie in België - Toestand op 31 December 2011. Brussels: WIV; 2012.
   Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med. 1998;338:853–60.
   PubMed Web of Science ®Google Scholar
• May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. Brit Med J. 2011;343:d6016.
   PubMed Web of Science ®Google Scholar
• Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet. 1998;351:723–4.
   PubMed Web of Science ®Google Scholar
• Knobel H, Carmona A, Grau S, Pedro-Botet J, Diez A. Adherence and effectiveness of highly active antiretroviral therapy. Arch Intern Med. 1998;158:1953.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
   PubMed Web of Science ®Google Scholar
• Mehta S, Moore RD, Graham NM. Potential factors affecting adherence with HIV therapy. Aids. 1997;11:1665–70.
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. Aids. 2000;14:357–66.
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Deeks SG. Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med. 2002;17:812–3.
   PubMed Web of Science ®Google Scholar
• Knobel H, Alonso J, Casado JL, Collazos J, Gonzalez J, Ruiz I, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. Aids. 2002;16:605–13.
   PubMed Web of Science ®Google Scholar
• Mannheimer SB, Mukherjee R, Hirschhorn LR, Dougherty J, Celano SA, Ciccarone D. The CASE adherence index: a novel method for measuring adherence to antiretroviral therapy. Aids Care. 2006;18:853–61.
   PubMed Web of Science ®Google Scholar
• Hoeymans N, van Lindert H, Westert GP. The health status of the Dutch population as assessed by the EQ-6D. Qual Life Res. 2005;14:655–63.
   PubMed Web of Science ®Google Scholar
• Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. Aids. 2010;24:1243–50.
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol — a new facility for the measurement of health-related quality of life. Health Policy. 1990;19:199–208.
   Google Scholar
• Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6:481–93.
   PubMed Web of Science ®Google Scholar
• Beck AT, Steer RA, Brown GK. Beck Depression Inventory II. San Antonio, TX: Psychological Corporation; 2002.
   Google Scholar
• Judd FK, Mijch AM. Depressive symptoms in patients with HIV infection. Aust NZ J Psychiat. 1996;30:104–9.
   PubMed Web of Science ®Google Scholar
• Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemoth. 2007;60:724–32.
   PubMed Web of Science ®Google Scholar
• Lang L, Nagi N, Gertner M, Masci M. HIV infected women: treatment adherence. Aids. 2000;14:S52.
   Web of Science ®Google Scholar
• Goujard C, Bernard N, Sohier N, Peyramond D, Lançon F, Chwalow J, et al. Impact of a patient education program on adherence to HIV medication — a randomized clinical trial. J Acquir Immune Defic. 2003;34:191–4.
   PubMed Web of Science ®Google Scholar
• Shuter J, Bernstein SL. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob Res. 2008;10:731–6.
   PubMed Web of Science ®Google Scholar
• Webb MS, Vanable PA, Carey MP, Blair DC. Medication adherence in HIV-infected smokers: the mediating role of depressive symptoms. Aids Educ Prev. 2009;21:94–105.
   PubMed Web of Science ®Google Scholar
• Shuter J, Bernstein SL, Moadel AB. Cigarette smoking behaviors and beliefs in persons living with HIV/AIDS. Am J Health Behav. 2012;36:75–85.
   PubMed Web of Science ®Google Scholar
• Lovejoy TI, Suhr JA. The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review. J Behav Med. 2009;32:389–405.
   PubMed Web of Science ®Google Scholar
• Ammassari A, Antinori A, Aloisi MS, Trotta MP, Murri R, Bartoli L, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45:394–402.
   PubMed Web of Science ®Google Scholar
• Knobel H. Are nonnucleoside analogue-based regimens better than protease inhibitor-based regimens for nonadherent HIV-infected patients? Clin Infect Dis. 2005;40:164–6.
   Web of Science ®Google Scholar
• Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother. 2008;61:769–73.
   PubMed Web of Science ®Google Scholar
• Gross R, Yip B, Lo Re V 3rd, Wood E, Alexander CS, Harrigan PR, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108–14.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Airoldi M, Kleinloog HD, Callegaro A, Ravasio V, Arici C, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8:282–92.
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. Plos ONE. 2008;3:e2783.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Hinkin CH, Marion S, Keuning A, Castellon SA, Lam MM, et al. Adherence to antiretroviral medications in HIV: differences in data collected via self-report and electronic monitoring. Health Psychol. 2006;25:329–35.
   PubMed Web of Science ®Google Scholar